U.S. flag

An official website of the United States government

NM_000143.4(FH):c.655G>A (p.Asp219Asn) AND Hereditary leiomyomatosis and renal cell cancer

Germline classification:
Benign (1 submission)
Last evaluated:
Apr 27, 2017
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001098958.5

Allele description [Variation Report for NM_000143.4(FH):c.655G>A (p.Asp219Asn)]

NM_000143.4(FH):c.655G>A (p.Asp219Asn)

Gene:
FH:fumarate hydratase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
1q43
Genomic location:
Preferred name:
NM_000143.4(FH):c.655G>A (p.Asp219Asn)
HGVS:
  • NC_000001.11:g.241508686C>T
  • NG_012338.1:g.16069G>A
  • NM_000143.4:c.655G>AMANE SELECT
  • NP_000134.2:p.Asp219Asn
  • NP_000134.2:p.Asp219Asn
  • LRG_504t1:c.655G>A
  • LRG_504:g.16069G>A
  • LRG_504p1:p.Asp219Asn
  • NC_000001.10:g.241671986C>T
  • NM_000143.3:c.655G>A
Protein change:
D219N
Links:
dbSNP: rs11545656
NCBI 1000 Genomes Browser:
rs11545656
Molecular consequence:
  • NM_000143.4:c.655G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Hereditary leiomyomatosis and renal cell cancer
Synonyms:
Reed syndrome; Multiple cutaneous and uterine leiomyomatosis; Cutaneous leiomyomata with uterine leiomyomata; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0007888; MedGen: C1708350; Orphanet: 523; OMIM: 150800; Human Phenotype Ontology: HP:0007437

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV001255361Illumina Laboratory Services, Illumina
criteria provided, single submitter

(ICSL Variant Classification Criteria 13 December 2019)		Benign
(Apr 27, 2017) 		germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Citation Link

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.

Eilers G, Czaplinski JT, Mayeda M, Bahri N, Tao D, Zhu M, Hornick JL, Lindeman NI, Sicinska E, Wagner AJ, Fletcher JA, Mariño-Enriquez A.

Mol Cancer Ther. 2015 Jun;14(6):1346-53. doi: 10.1158/1535-7163.MCT-14-0793. Epub 2015 Apr 7.

PubMed [citation]
PMID:
25852058
PMCID:
PMC4458458

Details of each submission

From Illumina Laboratory Services, Illumina, SCV001255361.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Jul 15, 2024